• Johnson & Johnson collaborates with Alameda Healthcare Group on Get Smart About Atrial Fibrillation campaign, raising awareness and education about Atrial Fibrillation, and cardiovascular disease.
• One out of four adults over the age of 40 is at risk of developing Atrial Fibrillation while over 40 million suffer from the condition across the globe.

As part of its commitment to raise awareness on cardiac conditions in Middle East, Johnson & Johnson MedTech has signed a collaboration agreement with Alameda Healthcare Group to raise awareness on Atrial Fibrillation (AF) and other cardiac arrythmias.

The initiative will focus on the Get Smart About AFIB campaign to raise awareness about Atrial Fibrillation disease, aiming to improve patient’s care and treatment. The ‘Get Smart About AFIB’ campaign https://getsmartaboutafib.net/ar-SA, was launched in Egypt last year, covering the entire Middle East region.

The joint campaign will focus on education and detection of the life-threatening Atrial Fibrillation condition that impacts nearly 40 million people globally. Atrial Fibrillation is the most common type of cardiac arrhythmias as one out of four adults over the age of 40 worldwide are at risk of developing the disease.

Doaa Ebada, Regional Director at Johnson & Johnson MedTech ME, said: “At Johnson & Johnson, we are committed to work closely with our partners in the government and private sector to educate patients, care professionals, and the community about Atrial Fibrillation, its chronic symptoms, and the importance of diagnosing and managing it. We strive  towards achieving our vision of building a society in which all enjoy a good quality of life, a healthy lifestyle, and an attractive living environment”.

“The campaign aims to raise awareness among patients about the disease, its symptoms, its causes as well as awareness programs for doctors on disease diagnosis and treatment”.

According to WHO, cardiovascular diseases are the leading cause of death globally, claiming an estimated 17.9 million lives each year and this is expected to rise to around 23.6 million by 2030.

While more than one-third of all deaths in the Middle East and North Africa region, which is almost 1.4 million people annually, are caused by cardiovascular disease.

Atrial Fibrillation, while not life threatening, can lead to more serious conditions like blood clots and stroke if not treated early, causing increased morbidity and mortality. There are many factors that increase the risk of developing Atrial Fibrillation during different stages of life, including medical problems, such as diabetes or kidney disease, as well as heart disease.

About Atrial Fibrillation

Atrial fibrillation (AFib or AF) is the most common form of cardiac arrhythmia and is characterized by an irregular and often fast heartbeat that results in uncoordinated contraction of the top two chambers of the heart (i.e. atria), It occurs when there is a fault in the electrical activity of the heart, causing the heart to beat in an irregular and uncoordinated fashion. It is typically a progressive condition, with 1 in 5 progressing from paroxysmal (intermittent) to persistent (constant) AFIB within 1 year. The symptoms of AFIB can have a devastating impact on those affected, with up to 47% of patients experiencing a reduction in their overall quality of life.

About Johnson & Johnson MedTech

Johnson & Johnson MedTech comprises the surgery, orthopedics, vision, and interventional solutions businesses within Johnson & Johnson's MedTech segment. At Johnson & Johnson MedTech, we unleash diverse healthcare expertise, purposeful technology, and a passion for people to transform the future of medical intervention and empower everyone to live their best life possible. For more than a century, we have driven breakthrough scientific innovation to address unmet needs and reimagine health. In surgery, orthopedics, vision, and interventional solutions, we continue to help save lives and create a future where healthcare solutions are smarter, less invasive, and more personalized.